Effect of the CYP2D6 gene polymorphism on postoperative analgesia of tramadol in Han nationality nephrectomy patients

被引:23
作者
Dong, Hong [1 ]
Lu, Shu-jun [1 ]
Zhang, Rui [1 ]
Liu, Dong-dong [1 ]
Zhang, Yan-zhuo [1 ]
Song, Chun-yu [1 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 2, China & Heilongjiang Key Lab Anesthesia & Crit Ca, Dept Anesthesiol, Harbin 150081, Heilonjiang, Peoples R China
关键词
Cytochrome P450 2D6; Tramadol; Postoperative analgesia; Han nationality; Nephrectomy; PAIN; PHARMACOKINETICS; PHARMACOGENETICS; POPULATIONS; METABOLISM; GENOTYPE; MAINLAND;
D O I
10.1007/s00228-015-1857-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Tramadol is a synthetic opioid which has analgesic efficacy in the postoperative pain. It is metabolized by polymorphic enzyme cytochrome P450 (CYP2D6). Patients with different CYP2D6 genotypes would have different responses to tramadol in pain relief. The CYP2D6*10 allele is the most common allele in a Chinese population. The aim of this study was to evaluate whether the different CYP2D6*10 genotypes have an effect on the postoperative tramadol analgesia in the Chinese population after elective nephrectomy. One hundred and twenty patients after performed elective nephrectomy were enrolled in this study after being approved by the local Ethics Committee. The patients were given patient-controlled analgesia (PCA) which included 10 mg/ml tramadol after receiving a loading dose of 100 mg tramadol and 1 mg granisetron intravenously. Blood samples were collected after induction of anesthesia. The CYP2D6*10 polymorphism was analyzed by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). According to the results, the patients were divided into three groups (CYP2D6*1/*1, n = 33; CYP2D6*1/*10, n = 28; CYP2D6*10/*10, n = 50). The total consumption of tramadol, visual analogue scale (VAS) score, and PCA control times among the three genotype groups for 2, 4, 24, 48, and 72 h after operation were compared. Nine out of 120 patients were dropped out of the study; 111 patients completed the study. The frequency of CYP2D6*10 allele was 57.7 %. The demographic data among the three groups were comparable. The consumption of tramadol, patient self-control times of pump, and VAS score in CYP2D6*10/*10 group were significantly higher than that in CYP2D6*1/*1 or CYP2D6*1/*10 group at 2 and 4 h (P < 0.05), while it did not differ between CYP2D6*1/*1 and CYP2D6*1/*10 group (P > 0.05). There was no difference in the incidence of nausea and vomiting among the three groups (P > 0.05). No sever apnea was recorded in these groups. Different CYP2D6*10 genotypes have an influence on the analgesic effect of tramadol in Han nationality patients after elective nephrectomy.
引用
收藏
页码:681 / 686
页数:6
相关论文
共 24 条
[1]   Concordance between tramadol and dextromethorphan parent/metabolite ratios: The influence of CYP2D6 and non-CYP2D6 pathways on biotransformation [J].
Abdel-Rahman, SM ;
Leeder, JS ;
Wilson, JT ;
Gaedigk, A ;
Gotschall, RR ;
Medve, R ;
Liao, S ;
Spielberg, SP ;
Kearns, GL .
JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (01) :24-29
[2]   Analgesic efficacy of topical tramadol in the control of postoperative pain in children after tonsillectomy [J].
Akbay, Buket Kocaman ;
Yildizbas, Sahnur ;
Guclu, Ender ;
Yilmaz, Suleyman ;
Iskender, Abdulkadir ;
Ozturk, Ozcan .
JOURNAL OF ANESTHESIA, 2010, 24 (05) :705-708
[3]  
Bachmann Kenneth A, 2002, Am J Ther, V9, P309, DOI 10.1097/00045391-200207000-00008
[4]   Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update [J].
Crews, K. R. ;
Gaedigk, A. ;
Dunnenberger, H. M. ;
Leeder, J. S. ;
Klein, T. E. ;
Caudle, K. E. ;
Haidar, C. E. ;
Shen, D. D. ;
Callaghan, J. T. ;
Sadhasivam, S. ;
Prows, C. A. ;
Kharasch, E. D. ;
Skaar, T. C. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (04) :376-382
[5]   Clinical pharmacology of tramadol [J].
Grond, S ;
Sablotzki, A .
CLINICAL PHARMACOKINETICS, 2004, 43 (13) :879-923
[6]  
Ji L, 2002, CHINESE MED J-PEKING, V115, P1780
[7]  
Kitada M, 2003, INT J CLIN PHARM RES, V23, P31
[8]   TRAMADOL - A PRELIMINARY REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC POTENTIAL IN ACUTE AND CHRONIC PAIN STATES [J].
LEE, CR ;
MCTAVISH, D ;
SORKIN, EM .
DRUGS, 1993, 46 (02) :313-340
[9]   CYP2D6 in the Metabolism of Opioids for Mild to Moderate Pain [J].
Leppert, Wojciech .
PHARMACOLOGY, 2011, 87 (5-6) :274-285
[10]   Relationship of CYP2D6 genetic polymorphisms and the pharmacokinetics of tramadol in Chinese volunteers [J].
Li, Q. ;
Wang, R. ;
Guo, Y. ;
Wen, S. ;
Xu, L. ;
Wang, S. .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2010, 35 (02) :239-247